Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> Developmental Biology Research RBRC05522 FLP/frt system Benoit de Crombrugghe Benoit de Crombrugghe Sox9-CreERT2 KI, Sox9-CreERT2 knock-in, B6-Sox9 KI/CreER Sox9-CreERT2 KI, Sox9-CreERT2 knock-in, B6-Sox9 KI/CreER Heterozygote x Wild-type [C57BL/6] Heterozygote x Wild-type [C57BL/6] B（1〜3か月） AB1 [129S7/SvEvBrd-Hprt<+>] Developed by Haruhiko Akiyama, The University of Texas MD Anderson Cancer Center. The knock-in vector was electroporated into AB1 ES cells. The mutant mice were crossed to C57BL/6. 条件を付加する。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。Genesis., 48, 635-644 (2010). <br>In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR and Dr. Haruhiko Akiyama, Kyoto University, is requested. Depositor retains ownership of the Biological Resource, including any Biological Resource contained in any modification. Any Biological Resource delivered pursuant to the Agreement is understood to be experimental in nature and may have hazardous properties. The DEPOSITOR MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE BIOLOGICAL RESOURCE WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. In no event shall Depositor be liable for any use by recipient of the Biological Resource for any loss, claim, damage or liability, of whatsoever kind of nature, which may arise from or in connection with the use, handling or storage of the Biological Resource. Except where limited by Federal law, or by the constitution and laws of the state governing the recipient, the recipient agrees to hold harmless Depositor and The University of Texas System and their Regents, officers, agents and employees, from any liability, loss or damage they may suffer as a result of claims, demands, costs or judgments against them arising out of recipient’s use of the Material and the use by recipient of the results obtained from the Research. The Biological Resource and modifications containing the Biological Resource may only be transferred to non-profit institutions for academic research purposes. Sox9 CreERノックインマウス。Sox9発現組織特異的にタモキシフェン誘導性Cre recombinaseを発現する。 mouse Sox9 genomic DNA, EMCV internal ribosomal entry site (ires), bacteriophage P1 cre recombinase gene, human estrogen receptor binding domain (ERT2), mouse phosphoglycerate kinase promoter (PGK promoter), E. coli Neomycin resistance gene, bovine polyA signal, yeast FRT (flipase recombination target) sites The University of Texas MD Anderson Cancer Center・秋山治彦先生（2001）。C57BL/6背景。 Sox9 CreERノックインマウス。Sox9発現組織特異的にタモキシフェン誘導性Cre recombinaseを発現する。, <a href='https://brc.riken.jp/mus/pcr05522'>Genotyping protocol -PCR-</a> B (1-3 months) Cre/loxP system true In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Genesis., 48, 635-644 (2010). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR and Dr. Haruhiko Akiyama, Kyoto University, is requested. Depositor retains ownership of the Biological Resource, including any Biological Resource contained in any modification. Any Biological Resource delivered pursuant to the Agreement is understood to be experimental in nature and may have hazardous properties. The DEPOSITOR MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE BIOLOGICAL RESOURCE WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. In no event shall Depositor be liable for any use by recipient of the Biological Resource for any loss, claim, damage or liability, of whatsoever kind of nature, which may arise from or in connection with the use, handling or storage of the Biological Resource. Except where limited by Federal law, or by the constitution and laws of the state governing the recipient, the recipient agrees to hold harmless Depositor and The University of Texas System and their Regents, officers, agents and employees, from any liability, loss or damage they may suffer as a result of claims, demands, costs or judgments against them arising out of recipient’s use of the Material and the use by recipient of the results obtained from the Research. The Biological Resource and modifications containing the Biological Resource may only be transferred to non-profit institutions for academic research purposes. B6.129S7-Sox9<tm1(cre/ERT2)Haak> B6.129S7-Sox9<tm1(cre/ERT2)Haak> Sox9-CreER knock-in mice. These mice have a tamoxifen-inducible cre (CreERT2) at the Sox9 locus. IRES-CreERT2-pA and FRT-PGK-neo-bpA cassettes were inserted into the 3’ UTR of exon 3 of the Sox9 locus.